What the record says
BPC-157: 36 studies, 35 of them preclinical
A 2025 systematic review screened 544 articles published from 1993 to 2024 and kept 36 studies — 35 preclinical and one clinical.
HSS J 2025;21:485–495 ↗The single human study in that review was a retrospective series on unspecified chronic knee pain: 7 of 12 patients reported relief lasting more than six months after a single treatment.
HSS J 2025;21:485–495 ↗The same review reports no clinical safety data, and a second 2025 review counts only three human pilot studies in total and calls for properly designed trials before the compound is treated as anything else.
Curr Rev Musculoskelet Med 2025;18:611–619 ↗
Compared with TB-500 10 mg: TB-500 is sold alongside it as the other recovery compound, in the same vial format. The difference in the record: TB-500 has a controlled human trial of 72 subjects that missed both primary endpoints, BPC-157 has 35 preclinical studies and one 12-patient retrospective series.
Read the research desk



